|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
62,030,000 |
Market
Cap: |
271.69(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.48 - $21.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
11 |
Total Shares Sold |
168,303 |
293,400 |
293,400 |
298,772 |
Total Sell Value |
$3,127,242 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
Total People Sold |
4 |
5 |
5 |
5 |
Total Sell Transactions |
6 |
11 |
11 |
12 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wigginton Jon Marc |
Sr V.P., Clinical |
|
2014-10-01 |
4 |
AS |
$20.48 |
$102,400 |
D/D |
(5,000) |
0 |
|
- |
|
Wigginton Jon Marc |
Sr V.P., Clinical |
|
2014-10-01 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-09-02 |
4 |
AS |
$20.89 |
$173,721 |
D/D |
(8,316) |
5,000 |
|
- |
|
Wigginton Jon Marc |
Senior VP, Clinical Dev. |
|
2014-08-18 |
4 |
AS |
$20.52 |
$102,600 |
D/D |
(5,000) |
0 |
|
- |
|
Wigginton Jon Marc |
Senior VP, Clinical Dev. |
|
2014-08-18 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-06-30 |
4 |
AS |
$21.84 |
$174,720 |
D/D |
(8,000) |
13,316 |
|
- |
|
Risser Eric Blasius |
VP, Business Development |
|
2014-06-30 |
4 |
OE |
$0.94 |
$7,520 |
D/D |
8,000 |
21,316 |
|
- |
|
Saran Atul |
See RemarksOfficer |
|
2014-06-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,500 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-05-29 |
4 |
S |
$19.75 |
$216,184 |
D/D |
(10,946) |
43,205 |
|
- |
|
Stein Kathryn E |
Senior VP, Prd Dev & Reg Aff |
|
2014-05-29 |
4 |
OE |
$0.71 |
$7,772 |
D/D |
10,946 |
54,151 |
|
- |
|
Wigginton Jon Marc |
Sr VP, Clinical |
|
2014-04-01 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
286 Records found
|
|
Page 12 of 12 |
|
|